Targeted therapies for critical care
The first targeted therapeutics company focused on integrated solutions for critical illnesses, Endpoint Health combines novel and on-market therapeutics, companion diagnostics, and artificial intelligence into an integrated platform designed to improve outcomes in critically ill patients.
Diego Rey, CSO
Diego is currently co-founder, board member, and Chief Scientific Officer of Endpoint Health a targeted therapeutics company in critical care. Prior to Endpoint, Diego co-founded GeneWEAVE, a diagnostics company that develops diagnostic products for detecting infections and guiding antibiotic therapy. Started in 2010, GeneWEAVE raised $25M in venture financing and was acquired by Roche in 2015 for $425M. Diego is also a former visiting partner and currently an bio Expert at YC.